REFERENCES

Barde RK, Amrutkar RK, Narkhede MR, Nehete JY. Optimization of gastro retentive drug delivery system of labetalol hydrochloride using simplex centroid design. International Journal of Pharmaceutical Sciences and Research. 2011; 2(9): 2439-2445.

Belal F, Al-Shaboury S, Al-Tamra S. Spectrophotometric determination of labetalol in pharmaceutical preparations and spiked human urine. Il Farmaco . 2003; (58): 293-299.

Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. International Journal of Pharmaceutics. 2006; (316): 86-92.

Chien YW. Novel drug delivery systems. Drugs and the Pharmaceutical Sciences Vol. 50. Marcel Dekker: New York, NY. 1992: 797.

Conti S, Maggi L, Segale L, Machiste E, Conte U, Grenier P, Vergnault G. Matrices containing NaCMC and HPMC - 1. Dissolution performance characterization. International Journal of Pharmaceutics. 2007; (333): 136-142.

Drug, Influence of Combination of Hydrophobic and Hydrophlic Matrix Former. Research J. Pharm. and Tech. Oct.-Dec. 2008; 1(4): 410-413.

Emami J, Tavakoli N, Ahmed M. Formulation of sustained – release lithium carbonate matrix tablets: influence of hydrophilic materials on the release rate and in vitro-in vivo evaluation. J Pharm Pharmaceut Sci. 2004; 7(3): 338-344.

Fan TY, Wei SL, Yan WW, Chen DB, Chen JL. An investigation of pulsatile release tablets with ethylcellulose and Eudragit L as film coating materials and cross-linked polyvinylpyrrolidone in the core tablets. Journal of Controlled Release. 2001; 77: 245-251.

Fujisaki Y, Tsukune T, Funyu M, Okumura M, Ukigaya T. Development of Sustained-Release Tablets Containing Sodium Valproate: In Vitro and In Vivo Correlation. Drug Development and Industrial Pharmacy. 2006; 32: 207-217.

Genc L, Bilac H, Guler E. Studies on controlled release dimenhydrinate from matrix tablet formulations. Pharmaceutica Acta Helvetiae. 1999; 74: 43-49.

Hardy IJ, Cook WG, Melia CD. Compression and compaction properties of plasticised high molecular weight hydroxypropylmethylcellulose (HPMC) as a hydrophilic matrix carrier. International Journal of Pharmaceutics. 2006; (311): 26-32.

Karmarkar AB, Gonjari ID, Hosmani AH, Dhabale PN. Evaluation of in vitro dissolution profile comparison methods of sustained release tramadol hydrochloride liquisolid compact formulations with marketed sustained release tablets. Drug Discoveries & Therapeutics. 2010; 4(1):26-32.

Kibria G, Jalil RU. The effect of the ratio of two acrylic polymers on the in vitro release kinetics of ketoprofen from pellets prepared by extrusion and spheronisation technique. Pak. J. Pharm. Sci. 2008; 21(2): 92-97.

Kramar A, Turk S, Vrecer F. Statistical optimisation of diclofenac sustained release pellets coated with polymethacrylic films. International Journal of Pharmaceutics. 2003; (256): 43-52.

Kumar CS, Yesupadam P, Harika B, Deepika D, Leela LV, Sekhar CA. Formulation and evaluation of once-daily sustained release Aceclofenac prosophis juliflora gum matrix tablets. International Journal of Pharmaceutical Sciences Review and Research. March – April 2010; 1(2): 23-28.

Lakade SH, Bhalekar MR. Formulation and Evaluation of Sustained Release Matrix Tablet of Anti-Anginal Drug, Influence of Combination of Hydrophobic and Hydrophlic Matrix Former. Research J. Pharm. and Tech. Oct.-Dec. 2008; 1(4): 410-413.

Lamoudi L, Chaumeil JC, Daoud K. Development of gastro intestinal sustained release tablet formulation containing acryl-EZE and pH-dependent swelling HPMC K 15 M. Drug Development and Industrial Pharmacy. 2012; 38(5): 515-520.

Ma D, Djemai A, Gendron CM, Xi H, Smith M, Kogan J, Li L. Development of a HPMC-based controlled release formulation with hot melt extrusion (HME). Drug Development and Industrial Pharmacy. 2012; Early Online: 1-14.

Maeda A, Shinoda T, Ito N, Baba K, Oku N, Mizumoto T. Evaluating tamsulosin hydrochloride-released microparticles prepared using single-step matrix coating. International Journal of Pharmaceutics. 2011; (408): 84-90.

Qui Y, Howdard SC, Engh KR, Poska RP. Once-a-Day Controlled-Release Dosage Form of Divalproex Sodium I: Formulation Design and In Vitro/In Vivo Investigations. Journal of Pharmaceutical Sciences. 2003; 92(6): 1166-1174.

Rathbone MJ, Hadgraft J, Michael SR. Modified-release drug delivery technology. Drugs and the Pharmaceutical Sciences. Marcel Dekker: New York, NY. 2003; (126): 996.

Robinson JR. Sustained and controlled release drug delivery systems. Drugs and Pharmaceutical Sciences Vol. 6. Marcel Dekker: New York, NY. 1978: 773.

Sadeghi F, Ford JL, Rubinstein MH, Rajabi-Siahboomi AR. Study of drug release from pellets coated with Surelease contain-ing hydroxypropyl methylcellulose. Drug Dev Ind Pharm. 2000; 27(5): 419-430.

Sahib MN, Abdulameer SA, Rasul AA. Design and in vitro evaluation of prednisolone tablets as a potential colon delivery system. Asian Journal of Pharmaceutical and Clinical Research. Oct.-Dec. 2009; 2(4): 84-93.

Sanchez-Lafuente C, Teresa Faucci M, Fernandez-Arevalo M, Alvarez-Fuentes J, Rabasco AM, Mura P. Development of sus-tained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers. Int J Pharm. 2002;234(1-2):213-221.

Santos JV, Pina ME, Marques PM, Carvalho LA. New sustained release of Zidovudine Matrix tablets – cytotoxicity toward Caco-2 ells. Drug Development and Industrial Pharmacy. 2012; Early Online: 1-13.

Shanthi CN, Mahato AK, Gupta R. A review on captopril oral sustained/controlled release formulations. Int.J.Drug Dev. & Res. April-June 2010; 2(2): 40-46.

Siddique S, Khanam J, Bigoniya P. Development of Sustained Release Capsules Containing "Coated Matrix Granules of Metoprolol Tartrate". AAPS PharmSciTech. 2010; 11(3): 1306-1314.

Siepmann F, Siepmann J, Walther M, Macrae RJ, Bodmeier R. Review - Polymer blends for controlled release coatings. Journal of Controlled Release. 2008; 125: 1-15.

Takka S, Rajbhandari s, Sakr A. Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. European Journal of Pharmaceutics and Biopharmaceutics. 2001; 52: 75-82.

Tang L, Schwartz JB, Porter SC, Schanaare RL, Wigent RJ. Drug release from film-coated chlorpheniramine maleate nonpa-reil beads: effect of water-soluble polymer, coating level, and soluble core material. Pharm Dev Tech. 2000;5(3):383-390.

Tiwari BS, Murthy TS, Pai MR, Mehta PR, Chowdary PB. Controlled Release Formulation of Tramadol Hydrochloride Using Hydro-philic and Hydrophobic Matrix System. AAPS PharmSciTech. 2003; 4(3); Article 31.

Tsai T, San Y, Ho H, Wu J, Sheu M. Film-forming polymer-granulated excipients as the matrix materials for controlled release dosage forms. Journal of Controlled Release. 1998; 51: 289-299.

US 2005/0031546 A1. Abuse-proofed dosage form. Pub. Dt.: Feb. 10, 2005; Assignee: Gruenenthal GmbH (DE).

US 4,940,580. Sustained release labetalol tablets. Pub. Dt.: Jul. 10, 1990; Assignee: Schering Corporation (NJ).

US 5,334,392. Matrix tablet permitting the sustained release of indapamide after oral administration. Pub. Dt.: August 2, 1994; Assignee: Adir et Compagnie (Courbevoie, FR)

US 5,591,454. Method for lowering blood glucose. Pub. Dt.: Jan. 07, 1997; Assignee: Alza Corporation (CA).

US 5,914,131. Hydromorphone therapy. Pub. Dt.: June 22, 1999; Assignee: Alza Corporation (CA).

US 5,948,437. Pharmaceutical compositions using thiazepine. Pub. Dt.: Sept. 07, 1999; Assingee: Zeneca Limited (UK).

US 6,149,940. Tablet with controlled release of alfuzosine chlorhydrate. Pub. Dt.: Nov. 21, 2000; Assignee: Synthelabo (FR); Jagotec AB (Switzerland).

US 6,514,531. Controlled-release dosage forms comprising zolpidem or a salt thereof. Pub. Dt.: Feb. 04, 2003; Assignee: Sanofi-Synthelabo (FR).

US 6,930,129. Methods and devices for providing prolonged drug therapy. Pub. Dt.: Aug. 16, 2005; Assignee: Alza Corporation (CA).

US 7,476,403. Oral extended-release composition. Pub. Dt.: January 13, 2009; Assignee: Andrx Pharmaceuticals, LLC (Davie, FL).

US 7,731,989 . Gastric retained gabapentin dosage form. Pub. Dt.: June 08, 2010; Assignee: Depomed Inc., (CA).

US 7,919,116. Controlled release metformin formulations. Pub. Dt.: Apr. 05, 2011; Assignee: Andrx Labs, LLC (FL, US)

US 7,919,116. Controlled release metformin formulations. Pub. Dt.: April 5, 2011; Assignee: Andrx Labs, LLC (Davie, FL).

Vyas, S.P. and Khar R.K., Controlled drug delivery Concepts and Advances, 1st Edn., Vallabh Prakashan,New Delhi. 2002: 477-502.

WO/2009/117819. Methylphenidate Extended Release Therapeutic Drug Delivery System. Pub. Dt.: Oct. 01, 2009; Assignee: Pharmascience Inc. (CA).

Yadav K, Yadav D, Srivastava AK. Evaluation of hydrophilic, hydrophobic and waxy matrix excipients for sustained release tablets of Venlafaxine hydrochloride. Drug Development and Industrial Pharmacy. 2012; Early Online: 1-10.